United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pierre fabre ltd - vinorelbine tartrate - solution for infusion - 10mg/1ml

Ireland - English - HPRA (Health Products Regulatory Authority)

pierre fabre dermatologie - clobetasol propionate - cutaneous foam - 0.05% %w/w - corticosteroids, very potent (group iv)

Ireland - English - HPRA (Health Products Regulatory Authority)

pierre fabre ltd - vinorelbine tartrate - capsule, soft - 30 base milligrams - vinca alkaloids and analogues; vinorelbine

Ireland - English - HPRA (Health Products Regulatory Authority)

pierre fabre ltd - vinorelbine tartrate - capsule, soft - 80 base milligrams - vinca alkaloids and analogues; vinorelbine

Ireland - English - HPRA (Health Products Regulatory Authority)

pierre fabre ltd - vinorelbine tartrate - capsule, soft - 20 base milligrams - vinca alkaloids and analogues; vinorelbine

Singapore - English - HSA (Health Sciences Authority)

pierre fabre singapore pte ltd - vinorelbine ditartrate eqv vinorelbine (base) - injection - 10 mg/ml - vinorelbine ditartrate eqv vinorelbine (base) 10 mg/ml

United States - English - NLM (National Library of Medicine)

pierre fabre pharmaceuticals, inc. - propranolol hydrochloride (unii: f8a3652h1v) (propranolol - unii:9y8nxq24vq) - propranolol hydrochloride 4.28 mg in 1 ml - hemangeol oral solution contains the beta-adrenergic blocker propranolol hydrochloride and is indicated for the treatment of proliferating infantile hemangioma requiring systemic therapy. hemangeol is contraindicated in the following conditions: - premature infants with corrected age < 5 weeks - infants weighing less than 2 kg - known hypersensitivity to propranolol or any of the excipients [see description (11)] - asthma or history of bronchospasm - heart rate <80 beats per minute, greater than first degree heart block, or decompensated heart failure - blood pressure <50/30 mmhg - pheochromocytoma of 460 infants with proliferating infantile hemangioma requiring systemic therapy who were treated with hemangeol starting at 5 weeks to 5 months of age, 60% had complete or nearly complete resolution of their hemangioma at week 24 [see  clinical studies (14)]. safety and effectiveness for infantile hemangioma have not been established in pediatric

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pierre fabre ltd - busulfan - solution for infusion - 6mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pierre fabre ltd - clobetasol propionate - cutaneous foam - 500microgram/1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pierre fabre dermo-cosmetique - metronidazole - cutaneous cream - 7.5mg/1gram